The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation

References

• Jemal A, Murray T, Ward E, Samuels A, Tiwari T, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Fisher S G, Fisher R I. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004; 23: 6524–6534
   PubMed Web of Science ®Google Scholar
• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674
   PubMed Web of Science ®Google Scholar
• Horning S, Negrin R, Hoppe R, Rosenberg S, Chao N, Long G D, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404–409
   PubMed Web of Science ®Google Scholar
• Bierman P, Vose J, Anderson J, Bishop M, Kessinger A, Armitage J. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450
   PubMed Web of Science ®Google Scholar
• Rohatiner A, Freedman A, Nadler L, Lim J, Lister T. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 1994; 5(Suppl 2)143–146
   PubMed Web of Science ®Google Scholar
• Bastion Y, Brice P, Haioun C, Sonet A, Salles G, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262
   PubMed Web of Science ®Google Scholar
• Freedman A, Neuberg D, Mauch P, Soiffer R, Anderson K, Fisher D, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta R, Grenzelias D, Johnson P, Pappa V, Summers K, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-Up. J Clin Oncol 2000; 18: 527
   PubMed Web of Science ®Google Scholar
• Schouten H, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson H, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817–3823
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484–1489
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504–1508
   PubMed Web of Science ®Google Scholar
• Quintó L, Aponte J, Menéndez C, Sacarlal J, Aide P, Espasa M, et al. Relationship between haemoglobin and haematocrit in the definition of anaemia. Trop Med Int Health 2006; 11: 1295–1302
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Press O, Eary J, Gopal A, Liu S, Rajendran J, Maloney D, et al. A phase I/II trial of high dose iodine-131-anti-B1 (anti CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas. Proc Am Soc Clin Oncol 1998; 17: 3a
   Google Scholar
• Gopal A, Gooley T, Maloney D, Petersdorf S, Eary J, Rajendran J, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351–2357
   PubMed Web of Science ®Google Scholar
• Chen C, Roitman D, Tsang R, Stewart A, Keating A, Crump M. ‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 885–891
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage J, Spitzer G, Chauvin F, Jagannath S, Cahn J, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Takvorian T, Canellos G, Ritz J, Freedman A, Anderson K, Mauch P, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499–1505
   PubMed Web of Science ®Google Scholar
• Vose J, Anderson J, Kessinger A, Bierman P, Coccia P, Reed E, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1851
   PubMed Web of Science ®Google Scholar
• Kaminski M, Zelenetz A, Press O, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918–3928
   PubMed Web of Science ®Google Scholar
• Witzig T, Gordon L, Cabanillas F, Czuczman M, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non- Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López A, Link B, Levy R, Czuczman M, Williams M, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• O'Connor O, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
   PubMed Web of Science ®Google Scholar
• Vose J, Bierman P, Enke C, Hankins J, Bociek G, Lynch J, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467
   PubMed Web of Science ®Google Scholar
• Knop S, Jakob A, Kanz L, Hebart H, Bares R, Dohmen B. 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2004; 103: 1175
   PubMed Web of Science ®Google Scholar
• Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896–2902
   PubMed Web of Science ®Google Scholar
• Khouri I, Saliba R, Giralt S, Lee M, Okoroji G, Hagemeister F, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599
   PubMed Web of Science ®Google Scholar
• Leonard J, Coleman M, Ketas J, Ashe M, Fiore J, Furman R, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 5044–5051
   PubMed Web of Science ®Google Scholar
• Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol 2004; 15: 1413–1418
   PubMed Web of Science ®Google Scholar
• Gopal A, Pagel J, Hedin N, Press O. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004; 103: 3516–3520
   PubMed Web of Science ®Google Scholar